Recent Company News

• 07:25 AM ET Jul 28, 2026
  

  RedHill updates on opaganib emergency outbreak development ($0.70, 0.00)

• 07:00 AM ET Jul 28, 2026
  

  Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development

• 09:10 AM ET Jun 30, 2026
  

  Jaguar Health provides additional results of evaluation of crofelemer as adjunctive oral therapy for the treatment of Pediatric intestinal failure at ESPGHAN 2026 ($2.96, 0.00)

• 08:58 AM ET Jun 18, 2026
  

  StreetAccount Summary - US Initial Syndicate recap for 18-Jun

• 08:03 AM ET Jun 18, 2026
  

  RedHill Biopharma announces up to $19.4M private placement at combined purchase price of $0.70 per ADS and accompanying warrants ($0.79, 0.00)

• 07:07 AM ET Jun 09, 2026
  

  RedHill'announced that the FDA has granted rare pediatric disease (RPD) designation to opaganib for treatment of neuroblastoma (NB) ($1.02, 0.00)

• 07:10 AM ET Jun 08, 2026
  

  RedHill launches enforcement of $11M New York Supreme Court final judgment against Kukbo ($1.03, 0.00)

• 12:08 PM ET Jun 03, 2026
  

  RedHill Biopharma fournit une mise à jour concernant l’opaganib et Ebola ($1.01, 0.00)

• 12:08 PM ET Jun 03, 2026
  

  RedHill Biopharma provides update regarding opaganib and Ebola ($1.01, 0.00)